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Cyclin T1 (CycT1) is a cellular transcription elongation factor that also participates in Tat-mediated activation of several lentiviral
promoters. In human immunodeficiency virus (HIV), CycT1 is required for Tat to bind tightly to TAR and interacts in the ternary complex via
its Tat–TAR recognition motif (TRM). In the related bovine immunodeficiency virus (BIV), Tat recognizes its cognate TAR element with high
affinity and specificity in the absence of CycT1. At both promoters, CycT1 recruits the Cdk9 kinase, which phosphorylates RNA polymerase II
to generate processive transcription complexes. To examine the physical properties of CycT1, we purified a functional domain corresponding
to residues 1–272 and found that it possesses a stably folded core, as judged by partial proteolysis and circular dichroism experiments.
Interestingly, the C-terminal 20 residues corresponding to the TRM appear conformationally flexible or disordered. The TRM of the bovine
CycT1 (bCycT1) is similarly sensitive to proteolysis yet differs in sequence from the human protein. In particular, bCycT1 lacks a cysteine at
residue 261 known to be critical for HIV but not BIV ternary complex formation, and mutagenesis data are consistent with a proposed role for
this cysteine in metal binding. The apparent flexibility of the TRM suggests that conformational rearrangements may accompany formation of
CycT1–Tat–TAR ternary complexes and may contribute to different TAR recognition strategies in different lentiviruses.
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Like many complex retroviruses, human immunodefi-
ciency virus (HIV) utilizes several virally encoded regulatory
proteins during its replication life cycle. One essential
regulatory protein, Tat, is required to stimulate RNA poly-
merase II-mediated transcription initiated from the 5V long-
terminal repeat (LTR) of the integrated proviral genome. Tat
binds to an RNA hairpin in the 5V LTR, known as the
transactivating response (TAR) element, and enhances tran-
scription processivity (for review, see Karn, 1999). One key
cellular protein, cyclin T1 (CycT1), was found to interact
with Tat and TAR (Wei et al., 1998) and, along with its
associated cyclin-dependent kinase (Cdk9), is part of a0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: frankel@cgl.ucsf.edu (A.D. Frankel).transcription elongation complex known as P-TEFb (Jones,
1997; Price, 2000). A current working model suggests that
Tat recruits P-TEFb to the nascent viral transcripts, allowing
Cdk9, and possibly other kinases, to hyperphosphorylate the
C-terminal domain (CTD) of polymerase and render it
processive (Majello et al., 1999; Napolitano et al., 2000).
Two functional domains in Tat have been identified: an
arginine-rich RNA-binding domain (residues 49–57) that
recognizes a bulge region of TAR (Aboul-ela et al., 1995;
Calnan et al., 1991; Long and Crothers, 1999; Puglisi et al.,
1992; Roy et al., 1990; Weeks and Crothers, 1991), and an
activation domain (residues 1–48) that interacts with CycT1
and increases the affinity and specificity for TAR (Bieniasz
et al., 1998; Chen et al., 1999; Fujinaga et al., 1999; Garber
et al., 1998; Ivanov et al., 1999; Kwak et al., 1999; Wei et
al., 1998). In the context of this ternary complex, the central
loop nucleotides of TAR are crucial for binding, consistent
with the known loop requirements for Tat-mediated activa-
tion in vivo (Feng and Holland, 1988; Madore and Cullen,
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suggest that residues between 252 and 261 of CycT1
directly contact nucleotides in the loop and may also help
position Tat near the loop (Richter et al., 2002b). It is
currently unclear whether CycT1 causes conformational
changes in Tat that permit interactions with the loop.
CycT1 is 726 amino acids in length, with residues 1–272
sufficient to form complexes with Tat and TAR and mediate
Tat activation (Bieniasz et al., 1998; Chen et al., 1999;
Fujinaga et al., 1998; Garber et al., 1998; Ivanov et al.,
1999). A region near the C terminus of CycT1 1–272,
termed the Tat–TAR recognition motif (TRM), is important
for forming Tat–CycT1–TAR ternary complexes (Bieniasz
et al., 1998; Fujinaga et al., 1999; Garber et al., 1998). The
TRM is one of the least conserved regions of CycT1, which
otherwise show >96% sequence identity among species.
Indeed, differences in the TRM sequence provided important
proof that CycT1 is an essential Tat cofactor. It had long been
known that Tat functions poorly in rodent cells, and it was
discovered that substituting Tyr261 of mouse cyclin T1
(mCycT1) with a cysteine residue found in the human cyclin
(hCycT1) fully rescued Tat activation in mouse cells (Bien-
iasz et al., 1998; Chen et al., 1999; Fujinaga et al., 1999;
Garber et al., 1998; Kwak et al., 1999; Wei et al., 1998). Here
we present biochemical evidence that CycT1 1–272 contains
a well-folded core with substantial a-helical content, as in
other types of cyclins, but that the C-terminal TRM, includ-
ing Cys261, is conformationally flexible.
Studies of other lentiviral Tat proteins have further
demonstrated the functional importance of CycT1 in Tat-
mediated activation. The Tat protein from equine infectious
anemia virus (EIAV) can activate the EIAV LTR using
equine or canine CycT1, but not hCycT1 (Albrecht et al.,
2000; Taube et al., 2000). Substituting residues 29, 79, and
80 of hCycT1 with the corresponding residues of equine
CycT1 rescued activity (Albrecht et al., 2000; Taube et al.,
2000). Interestingly, the equine and canine cyclins contain a
cysteine at position 261, like hCycT1, and support activation
of the HIV LTR by HIV Tat, further indicating that important
species-specific differences exist among different Tat–
cyclin–TAR complexes (Albrecht et al., 2000; Taube et
al., 2000).
Bovine immunodeficiency virus (BIV) and the closely
related bovine Jembrana disease virus (JDV) show yet other
differences in the assembly of Tat–TAR complexes and
different sequence requirements for the TRM. The argi-
nine-rich RNA-binding domain of BIV Tat adopts a h-
hairpin conformation and recognizes BIV TAR with high
affinity in the absence of CycT1, utilizing several amino side
chains to make sequence-specific RNA contacts (Chen and
Frankel, 1994, 1995; Puglisi et al., 1995; Ye et al., 1995). In
contrast, the HIV Tat RNA-binding domain binds HIV TAR
at least an order of magnitude more weakly in the absence of
hCycT1, utilizing one arginine from an extended peptide
chain to make a sequence-specific contact (Aboul-ela et al.,
1995; Calnan et al., 1991; Puglisi et al., 1992). The loopnucleotide sequence of BIV TAR is not important for BIV
Tat binding or activation (Chen and Frankel, 1994, 1995),
and activation through the BIV Tat–TAR interaction is
supported in murine, lapine, and human cells, further sug-
gesting a relaxed requirement for CycT1 (Barboric et al.,
2000; Bogerd et al., 2000; Chen and Frankel, 1994).
To further examine species-specific differences among
CycT1 proteins, we cloned the bovine CycT1 (bCycT1) and
compared its biochemical behavior to that of hCycT1. Like
mCycT1, bCycT1 lacks a cysteine at position 261 and is
unable to support HIV Tat function. Like hCycT1, partial
proteolysis of bCycT1 1–272 showed apparent conforma-
tional flexibility at its C terminus, consistent with the
relatively poor sequence conservation of the TRM. Muta-
genesis of residue 261 is consistent with the hypothesis that
the C-terminal region binds a metal ion near the Tat-binding
interface, perhaps utilizing Cys261 as a metal ligand as
previously proposed (Garber et al., 1998). Differences be-
tween hCycT1 and bCycT1 in the flexible C-terminal region
may affect interactions at the Tat–CycT1 interface and
contribute to differences in the HIV and BIV TAR recogni-
tion strategies.Results
Purified recombinant hCycT1 is monomeric
To begin to examine the biochemical properties and
structural details of CycT1, we generated a series of bacterial
expression vectors in which fragments of hCycT1 cor-
responding to predicted endpoints of the secondary structure
(residues 1–272, 1–317, and 1–420) were fused to GST (in
a pGEX2T vector) or expressed directly (in a pET21d
vector). The nonfused hCycT1 fragment (residues 1–272)
was expressed most highly, with approximately 50% in a
soluble form (Fig. 1A), and we refer to this functional
fragment as hCycT1 throughout the paper. We developed a
two-step purification protocol utilizing hydrophobic affinity
and anion exchange chromatography that produced prepara-
tions of >95% purity (Fig. 1A). Mass spectrometry indicated
a molecular mass of 31535 F 20 Da, in agreement with the
calculated mass of 31533 Da. hCycT1 is predominantly
monomeric as judged by size exclusion chromatography
(Fig. 1B). RNA-binding gel shift assays showed formation
of loop-dependent HIV Tat–CycT1–TAR complexes (C.D.
and A.D.F., in preparation) as previously observed (Fujinaga
et al., 1999; Ivanov et al., 1999; Richter et al., 2002a; Wei et
al., 1998; Zhou et al., 1998).
hCycT1 is helical and moderately stable
To assess the degree of hCycT1 folding, secondary struc-
ture, and protein stability, we recorded CD spectra and
performed thermal and chemical denaturation experiments.
The spectrum of hCycT1 (Fig. 2A) is characteristic of a
Fig. 2. Circular dichroism spectroscopy of hCycT1. (A) The spectrum of
hCycT1 was recorded at 4 jC in 10 mM K2HPO4 and 70 mM KF at 75 F
20 Ag/ml protein and mean residue ellipticity was calculated. The minima
near 222 and 208 nm are indicative of a helix. (B) The CD signal was
recorded at 222 nm as a function of increasing temperature (filled circles),
followed immediately by a reverse melt (open circles). (C) The CD signal
was recorded at 222 nm as a function of increasing guandinium
hydrochloride concentration, with a Cm observed at approximately 1.8 M.
Fig. 1. Expression and purification of hCycT1 1–272. (A) E. coli expression
levels and solubility of hCycT1 were assessed by running samples of crude
lysate and equivalent amounts of the insoluble fraction on SDS-PAGE gels
and staining with Coomassie blue. The lysates from uninduced BL21(DE3)
cells transformed with the pET21d expression vectors are shown as controls.
hCycT1 was purified using hydrophobic interaction (butyl) and anion
exchange (Q-Sepharose) FPLC columns, resulting in protein of >95%
purity. (B) Elution profile of hCycT1 from a Sephacryl S-100 size exclusion
column, with protein standards used for calibration.
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of 50%.We next examined protein stability bymonitoring the
CD melting curve at 222 nm (Fig. 2B) and observed a
cooperative unfolding transition with an apparent Tm of
approximately 45 jC. The melting curve was not reversible,
probably due to protein aggregation. To better estimate
protein stability, we monitored denaturation induced by
guanidinium hydrochloride and again observed a cooperative
unfolding transition (Fig. 2C), with a Cm of approximately
1.7 M at 4 jC. Thus, hCycT1 appears well folded and has a
helical secondary structure characteristic of other cyclins
(Andersen et al., 1996, 1997; Brown et al., 1995; Card et
al., 2000; Kim et al., 1996; Kobayashi et al., 1992; Russo et
al., 1996), but it appears to be only moderately stable.
The TRM of hCycT1 is sensitive to proteolysis
To examine the folding and stability of hCycT1 in more
detail, we performed limited proteolysis using chymotryp-
sin, trypsin, or subtilisin and examined the digestion prod-
ucts by sodium dodecyl sulfate polyacrylamide gels (SDS-
PAGE). In all cases, a predominant approximately 29-kDa
fragment (approximately 2.5 kDa shorter than hCycT1 1–
272) was produced within the first few minutes of cleavageand was the only product observed after 1 h (Fig. 3A shows
cleavage by chymotrypsin). This proteolytically stable frag-
ment from chymotryptic digestion was transferred to a
PVDF membrane and sequenced by Edman degradation.
The first six residues, MEGERK, corresponded to the intact
N terminus of hCycT1, indicating that cleavage had oc-
curred near the C terminus.
We used mass spectrometry to map the cleavage site
more precisely. After 15 min of digestion with chymotryp-
sin, we observed uncleaved hCycT1 along with two diges-
tion products that corresponded to cleavage after Trp256
and Leu252 (Fig. 3B). The amino acid assignments are
consistent with the reduction in mass of approximately 2
and 2.5 kDa observed by gel and the known preference of
chymotrypsin to cleave after hydrophobic residues. Thus, it
appears that the C-terminal 20 amino acids of hCycT1,
which includes the TRM and Cys261, may be disordered or
near a proteolytically sensitive loop.
We wished to ensure that the C-terminal proteolytic
sensitivity was not caused by the somewhat arbitrary trun-
cation of full-length hCycT1 at residue 272, which might
have disrupted an important element of secondary or tertiary
Fig. 3. Partial proteolysis of CycT1 proteins. (A) Time course of chymotrypsin digestion at a 1:60 chymotrypsin/hCycT1 ratio monitored by SDS-PAGE. (B)
MALDI-TOF mass spectrometry of the hCycT1 chymotryptic products from A. Before cleavage (0 min), the measured mass to charge ratio was 31560 F 20
(calculated value = 31533). After 15 min of digestion, two cleavage products were observed with masses of 29680 F 70 (calculated value for cleavage after
Trp256 = 29679) and 29080F 40 (calculated value for cleavage after Leu252 = 29096). After 60 min of digestion, only the smaller fragment (29076F 30) was
observed. (C) Time course of chymotrypsin digestion of in vitro translated hCycT1 1–272 and 1–420 (approximately 1:100 chymotrypsin:hCycT1) monitored
by SDS-PAGE.
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of hCycT1 by bacterial expression to test whether cleavage
would still occur at the same position; however, we could
successfully produce hCycT1 residues 1–420 by in vitro
translation. As shown in Fig. 3C, chymotryptic digestion ofFig. 4. Multiple sequence alignment of residues 1–272 from bCycT1 (bovine), h
indicate positions that differ in any pairwise combination, closed circles indicate th
arrow marks the important residue at position 261.in vitro translated 1–420 or 1–272 fragments resulted in
identical approximately 29-kDa products even after 1 min of
digestion (corresponding to cleavage at Leu252), strongly
suggesting that the site is truly accessible in its native
context.CycT1 (human), and mCycT1 (murine) by ClustalW (version 1.81). Boxes
e nine positions that differ between the bovine and human proteins, and an
Fig. 5. (A) Activities of bCycT1, hCycT1, and mCycT1 in HIV Tat-
mediated activation of the HIV LTR. Mouse NIH 3T3 cells were co-
transfected with 20 ng of a pHIV-LTR-CAT reporter, 100 ng of the
pSV2tat72 Tat expression plasmid, and the indicated concentrations of
pcDNA3 CycT1 expression plasmids. Fold activation was calculated by
normalizing to the levels of CAT expression in the absence of cotransfected
CycT1. (B) Activities of bCycT1 variants at position 261 in HIV Tat-
mediated activation of the HIV LTR. Mouse NIH 3T3 cells were co-
transfected with 10 ng of a pHIV-LTR-CAT reporter, 100 ng of the
pSV2tat72 Tat expression plasmid, and 20 ng of pcDNA3 CycT1
expression plasmids. Fold activation was calculated as in A. (C) Activities
of CycT1 N-terminal deletion mutants in HIV Tat-mediated activation of
the HIV LTR. Mouse NIH 3T3 cells were co-transfected with 10 ng of a
pHIV-LTR-CAT reporter, 100 ng of the pSV2tat72 Tat expression plasmid,
and 50 ng of pcDNA3 CycT1 expression plasmids. Fold activation was
calculated as in A.
Fig. 6. (A) Time course of chymotrypsin digestion of in vitro translated
human and bovine CycT1 1–272 (approximately 1:100 chymotrypsin/
CycT1) monitored by SDS-PAGE. (B) Time course of chymotrypsin
digestion of in vitro-translated human and bovine CycT1 1–420
(approximately 1:100 chymotrypsin/CycT1).
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As described in the Introduction, the Tat–TAR com-
plexes of different lentiviruses show rather distinct modes of
binding and dependence on CycT1. For example, the HIV
Tat–TAR complex requires hCycT1 and Cys261 in the
TRM whereas the BIV Tat–TAR complex forms with highaffinity in the absence of CycT1. To examine the biochem-
ical and functional behavior of a CycT1 TRM that is not
essential for TAR recognition, we next cloned bCycT1 from
a cDNA library based on nucleotide sequence conservation
between hCycT1 and mCycT1. The alignment of amino
acids 1–272 (Fig. 4) shows that bCycT1 and hCycT1 are
97% identical in this region and about as similar as hCycT1
and mCycT1 (96% identity). Of the nine amino acid differ-
ences between bCycT1 and hCycT1, most notable is tryp-
tophan at position 261 in place of the critical cysteine in
hCycT1. In mCycT1, which does not support HIV Tat
activation, residue 261 is a tyrosine (Bieniasz et al., 1998;
Chen et al., 1999; Fujinaga et al., 1999; Garber et al., 1998;
Kwak et al., 1999; Wei et al., 1998). The full-length bCycT1
(728 residues) is 81% identical to hCycT1 but is even more
closely related (89% identity) to caprine CycT1, which also
has a tryptophan at position 261 (Mata and Vilotte, 2002).
Activity of bCycT1 requires a metal ligand at position 261
Because BIV Tat binds BIV TAR in a CycT1-indepen-
dent mode, it is able to activate transcription in a variety of
cell types, including rodent cells that express CycT1 with
Tyr261 and are therefore nonpermissive for HIV Tat acti-
vation (Barboric et al., 2000; Bogerd et al., 2000; Chen and
Frankel, 1994). To test the activity of our cloned bCycT1,
we asked whether it could stimulate BIV Tat-mediated
activation of its cognate BIV LTR using CAT reporter
assays. No effect of bCycT1 was observed in either HeLa
or mouse NIH 3T3 cells (data not shown), as expected
because hCycT1 and mCycT1 are both able to support
activation in the BIV context (Barboric et al., 2000; Bogerd
et al., 2000). To provide a better context for monitoring
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HIV Tat-mediated activation of an HIV LTR CAT reporter
in mouse 3T3 cells, a context in which mCycT1 does not
function but in which multiple Cys261-containing CycT1s
can be introduced to complement activity (Bieniasz et al.,
1998; Chen et al., 1999; Fujinaga et al., 1999; Garber et al.,
1998; Kwak et al., 1999; Wei et al., 1998). Cotransfection of
hCycT1 resulted in a 20–30-fold increase in Tat-mediated
activation, as previously observed, whereas cotransfection
of bCycT1 or mCycT1 had no effect (Fig. 5A). Thus,
bCycT1 lacking Cys261 cannot complement the inactive
mCycT1.Fig. 7. Alignment of hCycT1 with other cyclins of known structure as calculated b
cyclin box and the conserved AxK in the third helix (marked by asterisks) allow fo
outside these regions are less certain. Double dots indicate positions of conservativ
changes. The structures of human CycA, human CycH, and g-herpesvirus Cyc
Schulze-Gahmen et al., 1999), are shown below as ribbon diagrams. The first 5-he
The N-terminal helices before the first bundle are colored in blue and the C-termin
three cyclins were aligned by overlapping the backbone atoms of the conserved ala
Ala112xLys114, CycA/Ala92xLys94, CycM/Ala102xK104) within the first helica
two repeats and N- and C-terminal regions.Given the similarities between bCycT1, mCycT1, and
hCycT1, we hypothesized that mutating residues in the C
terminus of bCycT1 might rescue the ability of bCycT1 to
activate the HIV LTR. Previous experiments have shown
that replacing Tyr261 of mCycT1 with Cys was sufficient
to restore function on the HIV LTR (Bieniasz et al., 1998;
Fujinaga et al., 1999; Garber et al., 1998; Kwak et al.,
1999). To examine the importance of this position in
bCycT1, we generated a set of mutants of Trp261 and
found that the W261C variant fully rescued activity to the
level of hCycT1, whereas Tyr (as in mCycT1), Ser, or Ala
mutants were inactive (Fig. 5B). A His replacementy ClustalW (top). The frequently observed alanine in the second helix of the
r identification of some secondary structure elements of CycT1. Alignments
e amino acid changes and single dots indicate positions of less conservative
M, determined by crystallography (Brown et al., 1995; Kim et al., 1996;
lix bundle in each is colored in green and the second 5-helix bundle in grey.
al regions after the second bundle are colored in red. The orientations of the
nine (CycH/Ala83, CycA/Ala236, CycM/Ala73) and AxK residues (CycH/
l bundle. The orientations shown highlight the variable arrangements of the
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this residue in metal binding (Garber et al., 1998) (see
below).
The C-terminal region of bCycT1 is sensitive to proteolysis
Given that the TRM of hCycT1 is proteolytically sensi-
tive and probably conformationally flexible or exposed, we
wished to determine whether the corresponding C-terminal
region of bCycT1 displayed similar behavior despite the
amino acid differences. We generated bCycT1 1–272 by in
vitro translation as we were unable to produce any soluble
form of bCycT1 by bacterial expression, and compared its
proteolytic sensitivity to that of the corresponding hCycT1
1–272 fragment. The chymotryptic time courses for both
were very similar, with a proteolytically stable approximate-
ly 29-kDa fragment seen even after 60 min of digestion
(Fig. 6). A similar approximately 29-kDa fragment was seen
after digestion of in vitro translated bCycT1 1–420, as also
observed with hCycT1 (Fig. 6), further indicating that the C-
terminal protease sensitivity did not result from the trunca-
tion at residue 272. Thus, it appears that the functionally
active 1–272 fragments of both hCycT1 and bCycT1 are
largely folded but contain a disordered or proteolytically
susceptible region near their C-termini.
The N-terminal region of CycT1 is not required for Tat-
mediated activation
Given that the proteolytically sensitive C-terminal region
of hCycT1 also corresponds to the TRM, we attempted to
model the position of the C terminus within the cyclin
domain to help identify other regions that might influence
the structure, and potentially the function, of the TRM. We
aligned the sequence of CycT1 with those of three other
cyclins (CycA, CycH, and CycM) whose structures are
known (Brown et al., 1995; Kim et al., 1996; Schulze-
Gahmen et al., 1999) and that are approximately the same
length as CycT1 1–272 (Fig. 7). All three contain a
conserved cyclin fold (two consecutive domains of five
helices each) and an extra N-terminal helix, but have
differing C-terminal structures and orientations of the ter-
mini (Fig. 7). In CycH, a C-type cyclin like CycT1, the N-
and C-termini are in close proximity, and we hypothesized
that the putative N-terminal helix of CycT1 might influence
the disordered C-terminal region, perhaps even maintaining
it in a proteolytically sensitive state. In CycH and CycM, the
N-terminal helices also contact their CdK partners (Ander-
sen et al., 1997; Schulze-Gahmen et al., 1999). To examine
the importance of this putative helix, we deleted the N-
terminal 27 residues of hCycT1 (generating 28–272), and
also of bCycT1 and mCycT1 to test whether deletion might
unmask activity, and measured their ability to stimulate HIV
Tat-mediated activation in the HIV LTR CAT reporter assay.
The deletions neither diminished hCycT1 activity nor en-
hanced the activity of bCycT1 or mCycT1 (Fig. 5C),suggesting that the N-terminal region is dispensable for
TAR binding and Tat-mediated activation.Discussion
We have characterized a hCycT1 fragment known to be
sufficient for HIV Tat-mediated activation (residues 1–
272) and found that the protein is largely helical, charac-
teristic of a cyclin fold. Interestingly, residues 1–252 form
a proteolytically resistant core whereas the C-terminal 20
amino acids, which includes the previously defined HIV
Tat–TAR recognition motif (TRM) and Cys261 known to
be essential for HIV Tat function (Bieniasz et al., 1998;
Fujinaga et al., 1999; Garber et al., 1998), appear to be
conformationally flexible or disordered. bCycT1, whose
sequence we report here, contains Trp at position 261 and
consequently does not function in HIV Tat-mediated acti-
vation; nevertheless, bCycT1 1–272 also shows a stable
core and a flexible C terminus similar to the human
protein.
The C-terminal region is the least conserved part of
CycT1, consistent with a flexible structure. Of the nine
amino acid differences between bCycT1 and hCycT1 within
residues 1–272, four are in the C-terminal region between
residues 261 and 265. Only the difference at position 261
appears functionally important, as mutation of Trp261 in
bCycT1 to Cys generates a protein active for HIV Tat-
mediated activation (Fig. 5B). Cys261 is not required for
activation of the BIV LTR by BIV Tat or of the HIV LTR
when Tat is delivered via the BIV Tat–TAR interaction,
which occurs with high affinity in the absence of CycT1
(Barboric et al., 2000; Bogerd et al., 2000; Chen and
Frankel, 1994). Thus, it appears that the critical importance
of Cys261 is coupled to a role in HIV TAR RNA recogni-
tion, presumably mediated by interactions between the C-
terminal TRM and HIV Tat. This is supported by cross-
linking experiments in which residues within 252–261 of
hCycT1 were found to crosslink to the HIV TAR loop in the
context of ternary complexes with Tat (Richter et al.,
2002b). It is not possible to definitively establish a role
for bCycT1 in BIV Tat-mediated activation because BIV Tat
functions in all cell types tested (bovine, human, murine,
and lapine) and apparently can utilize any of these CycT1s,
which share >79% sequence identity, or other cyclins to
recruit Cdk9 and function in transcription (Barboric et al.,
2000; Bogerd et al., 2000). Because BIV Tat binds with
high affinity to BIV TAR in a h-hairpin mode independent
of CycT1, it seems reasonable that the requirements for the
Tat–CycT1 interface may be more relaxed than in the HIV
complex.
There is some evidence that the flexible C-terminal
region of CycT1, and Cys261 in particular, may participate
in metal binding, at least in the HIV complex. Previous
RNA-binding experiments demonstrated Zn-dependent for-
mation of Tat–hCycT1–TAR complexes, leading to a
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interface (Garber et al., 1998). Our mutagenesis results
with bCycT1 support a role for position 261 in metal
binding and formation of ternary complexes on HIV TAR.
In particular, substitution of Trp261 with Cys rescued
activation of the HIV LTR, as is also the case with
mCycT1 (Bieniasz et al., 1998; Chen et al., 1999; Fujinaga
et al., 1999; Garber et al., 1998; Kwak et al., 1999; Wei et
al., 1998), and substitution with His, another potential Zn-
binding ligand, rescued approximately 25% of the activity
(Fig. 5B). The rescue of activity with His is interesting in
that a similar substitution in mCycT1 did not support
formation of HIV Tat–CycT1–TAR ternary complexes in
vitro (Garber et al., 1998), perhaps indicating that metal-
binding conditions or additional factors in vivo assist in
complex formation. Besides Cys261, there are 6 other
cysteines and 11 histidines within hCycT1 and bCycT1
1–272 that could serve as potential metal ligands. However,
a recent study has shown that mutating any of these residues
to alanine had no effect on HIV Tat activation (Koh et al.,
2002), suggesting that they are not metal ligands, that
individual mutations do not completely disrupt metal bind-
ing, or that their metal binding is not critical for Tat
function.
The bridging interaction between hCycT1 and HIV Tat
has been proposed to involve some of the seven cysteines in
the Tat activation domain that are essential for activity and
participate in the formation of metal-bridged homodimers in
vitro (Frankel et al., 1988; Rice and Carlotti, 1990; Ruben et
al., 1989). Interestingly, the activation domain of BIV Tat
preserves the seven cysteines (Chen and Frankel, 1994) yet
does not require Cys261 for activity, suggesting that inter-
actions between BIV Tat and, presumably, the C-terminal
region of bCycT1 are somewhat different than in the HIV
complex. Alternatively, it is possible that Cys261 directly
contacts HIV TAR and thereby contributes to loop-binding
specificity.
Our proteolysis results suggest that the C-terminal
regions of both hCycT1 and bCycT1 are conformationally
flexible or disordered. Previous studies have shown that the
HIV TAR loop in its unbound state is also flexible (Aboul-
ela et al., 1995; Huq et al., 1999), suggesting that mutually
induced conformational changes may occur in Tat, CycT1,
and TAR upon complex formation. It seems likely that any
induced structural changes, now observed in many ribonu-
cleoprotein complexes (see Frankel, 2000; Frankel and
Smith, 1998; Leulliot and Varani, 2001; Williamson, 2001
for recent reviews), will differ in the HIV and BIV com-
plexes, including possible metal-dependent interactions or
conformations, highlighting the need for more detailed
structural comparisons.
Conformational flexibility at the C terminus of cyclin
domains may be a common theme, and these are often
regions that interact with other proteins (Andersen et al.,
1997; Kobayashi et al., 1992). Studies of CycA and CycH
have reported disorder in the crystal structure at the end ofthe helical cyclin domain or proteolytic degradation of 20–
35 C-terminal residues (Brown et al., 1995; Kim et al.,
1996; Schulze-Gahmen et al., 1999). It seems reasonable
that this region of CycT1 is similarly disordered. In
general, the cyclins encompass a wide family of proteins
(for a review see Noble et al., 1997) defined by a cyclin
box motif that displays relatively weak sequence identity
but related patterns of hydrophobicity and helical propen-
sity (Gibson et al., 1994). The cyclin fold is roughly
defined as two repeats of 5-helix bundles, with the pair
often flanked by additional helices (Fig. 7). The first repeat
(the cyclin box) contains amino acids required for binding
target kinases or maintaining the cyclin fold, and these are
often the most, albeit weakly, conserved residues (Ander-
sen et al., 1996, 1997; Brown et al., 1995; Card et al.,
2000; Kim et al., 1996; Kobayashi et al., 1992; Russo et
al., 1996). The sequences of the second repeat are even
more variable, leading to a variety of tertiary arrangements
as demonstrated by the structures of the cell cycle regula-
tor CycA (Brown et al., 1995; Russo et al., 1996),
transcription factor CycH (Andersen et al., 1996; Kim et
al., 1996), and g-herpesvirus CycM (Card et al., 2000)
(Fig. 7). The relative orientation of the repeats, the
secondary structure of the regions surrounding the repeats,
and the relative orientations of the terminal helices are quite
different.
The diversity of cyclin sequence and structure prevents
us from developing a good homology-based model of
CycT1. hCycT1 was first described as a C-type cyclin
based on its sequence similarity to cyclin Pcht1(+) from S.
pombe (Wei et al., 1998), and thus the structure of CycH
(C-type) was previously used to model the possible posi-
tion of Cys261 (Garber et al., 2000; Taube et al., 2000).
Both studies placed Cys261 within the ‘extra’ helix C-
terminal to the second repeat, which also located it near the
N-terminal helix. This positioning was consistent with a
comparison between equine CycT1 and hCycT1 that iden-
tified N-terminal residues required for equine infectious
anemia virus (EIAV) Tat function (Taube et al., 2000),
although another study has reported conflicting results
(Albrecht et al., 2000). Nonetheless, it seems difficult to
draw strong conclusions about the position of the C-
terminal TRM in hCycT1 based on weak cyclin sequence
alignments and variable structural arrangements (Fig. 7),
and indeed, deletion of the presumed N-terminal helix does
not affect hCycT1 activity (Fig. 7). More studies are
needed to better position Cys261 and the TRM within the
hCycT1 structure.
Recent studies have shown that CycT1 plays a broader
role in regulating transcription elongation by binding the
small 7SK RNA in addition to CDK9 (Nguyen et al.,
2001; Yang et al., 2001). It will be of interest to determine
whether 7SK recognition is related to TAR recognition and
whether similar regions of CycT1, perhaps including the
C-terminal region, are involved in both RNA and protein
interactions.
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Plasmid construction
For CycT1 expression in bacteria, PCR fragments were
cloned into the NcoI and EcoRI sites of pET21d (Novagen).
Previously described pHIV LTR CAT reporter and
pSV2tat72 expression vectors (Frankel and Pabo, 1988;
Sodroski et al., 1985) were used for Tat activation assays
in mammalian cells. PCR fragments encoding the human,
bovine, and mouse CycT1 proteins (residues 1–272 or 28–
272) were cloned into the HindIII and EcoRI sites of
pcDNA3 (Invitrogen) and used for CycT1 expression.
PCR fragments for the human and mouse clones were
amplified from pGEX-2T expression vectors (kindly pro-
vided by Dr. K.A. Jones) (Garber et al., 1998), and frag-
ments for the bovine clones were amplified from the cDNA
phage stocks described below. Site-directed mutants of
bCycT1 were generated using PCR primers containing the
appropriate mutations. The sequences of all inserts were
confirmed (Biomolecular Resource Center, UCSF).
Protein expression and purification
The pET21d expression vectors for hCycT1 and bCycT1
were transformed into BL21(DE3) cells, single colonies
were inoculated into Luria broth (LB) containing 50 Ag/ml
ampicillin, cultures were grown at 30 jC, and protein
expression was induced at OD600 = 0.8 by adding 0.1 mM
IPTG for 6 h. Cells were lysed by sonication in 80 ml (per
l of culture) lysis buffer containing 20 mM Tris–Cl pH 8.0,
30 mM NaCl, 250 mM ammonium sulfate, 10% glycerol,
0.5% NP-40, 5 mM DTT, and 1 mM PMSF, and centri-
fuged. As described in Results, bCycT1 was insoluble and
could not be purified further in its native form. For hCycT1
(residues 1–272), the crude supernatant was applied to a
Butyl fast flow hydrophobic column (Pharmacia) equilibrat-
ed with lysis buffer, the column was washed with 20 column
volumes of lysis buffer, and protein was eluted in buffer A
(20 mM Tris–Cl pH 8.0, 30 mM NaCl, 5 mM DTT, 10%
glycerol). hCycT1 eluted as a single peak which was
dialyzed into buffer A, applied to a Q-Sepharose fast-flow
column (Pharmacia), and eluted in a 30–250 mM NaCl
gradient in buffer A. hCycT1 eluted at approximately 50
mM NaCl and was >95% pure.
Protein characterization
The purity of hCycT1 1–272 was estimated on Coomassie
blue-stained sodium dodecyl sulfate polyacrylamide gels
(SDS-PAGE), and protein concentrations were measured by
Bradford assays (Biorad). N-terminal sequences of hCycT1
or proteolytic fragments were determined by Edman degra-
dation of samples transferred to PVDF membranes (Dr.
Christoph Turck, Howard Hughes Medical Institute, UCSF).
Oligomeric state was assessed by analytical size exclusionchromatography on a Sephacryl S-100 column (Pharmacia).
hCycT1 (100 Ag) was loaded and eluted from the column in
buffer A, and the molecular weight was estimated by com-
paring elution volumes to size exclusion standards (Biorad).
Mass spectra were acquired using a Voyager-DEMALDI/
TOF mass spectrometer (PerSeptive Biosystems, Framing-
ham, MA) equipped with a nitrogen laser (k = 337),
single stage reflector, and timed ion selector, at an ion
path length of 1.2 m. Samples were collected in positive
ion-linear mode with delayed extraction, using an accel-
erating voltage of 20 K and 140 ns extraction delay time.
hCycT1 samples in 20 mM Tris–Cl buffer (pH 8.0), 30
mM NaCl, 0.5 mM DTT, and 10% glycerol were diluted
to approximately 1 AM in 10 mg/ml sinapinic acid, 0.3%
TFA, and 50% acetonitrile and dried on the sample target.
Three spectra were acquired for each sample and the
values reported are averages (Fstandard deviation), using
bovine a-chymotrypsinogen [M + H]+ = [25666] (aver-
age) and S. cerevisiae alcohol-dehydrogenase [M + H]+ =
[36685] (average) as external calibration standards. Theo-
retical molecular masses for hCycT1 1–272 and proteo-
lytic fragments (see below) were calculated from their
amino acid sequence using an internet-based calculator
(Swiss Institute of Bioinformatics; http://www.expasy.ch/
tools/pi_tool.html).
Circular dichroism (CD) spectra were recorded on an
Aviv 62DS spectropolarimeter at 4 jC in 10 mM K2HPO4
(pH 7.5) buffer and 70 mM KF (CD buffer). Ellipticity was
averaged for 4 s at 1-nm intervals. Helical content was
estimated from the mean residue ellipticity at 222 nm (Chen
et al., 1974). For thermal denaturation experiments, samples
were equilibrated by stirring for 1 min at 1 jC intervals from
4 jC to either 50 or 70 jC using thermoelectric temperature
control. For chemical denaturation experiments, aliquots of
8 M guanidinium hydrochloride (ultrapure, Sigma) were
added to hCycT1 1–272 initially at 0.1 mg/ml, and the
sample was equilibrated after each addition by stirring at 4
jC for >2 min. Ellipticity values at 222 nm were corrected
for protein dilution, and protein stability was calculated by
linear extrapolation of the melting curve to zero guanidi-
nium (Schmid, 1989).
Partial proteolysis
Proteolysis of purified hCycT1 was performed in CD
buffer by incubating 0.79 nmol hCycT1 (24 Ag) at 22 jC
with 0.4 Ag of a-chymotrypsin (TLCK treated, Sigma),
trypsin (TPCK treated, Boehringer Mannheim), or subtilisin
(Boehringer Mannheim). At each time point, one-tenth of
the reaction mixture was removed and quenched by adding
SDS-PAGE buffer and heating at 90 jC for 5 min, and
analyzed on gels. To prepare proteolyzed samples for mass
spectrometry, chymotryptic reactions were carried out in 20
mM Tris–Cl buffer (pH 8.0), 30 mM NaCl, 0.5 mM DTT,
and 10% glycerol at approximately 1:100 chymotrypsin/
hCycT1, and the reactions were quenched at appropriate
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sample plates. Partial proteolysis was also performed on in
vitro-translated hCycT1 and bCycT1 proteins. Proteins were
synthesized in coupled rabbit reticulocyte transcription–
translation reactions by adding 40 Al of the premixed
cocktail (Invitrogen) to 2 Al of 35S-labeled methionine and
0.5–1 Ag of template DNA and incubating at 30 jC for 2 h.
Partial proteolysis was performed with 5 Al of protein
translation mixture and 0.04 Ag of chymotrypsin, and
0.95-Al aliquots were removed and quenched as above at
appropriate time points.
bCycT1 cloning
Initial PCR primers were designed based on highly
conserved nucleotide sequences within hCycT1 and
mCycT1 (5V-CCG GAT CCA TAT GGA GGG AGA GAG
GAA GAA C-3V and 5V-AAC TGG ATC CTC ACT CAC
TAG TCC GAT GAC CCT G-3V). A 1069-nt fragment near
the 5Vend of the gene was amplified from a bovine cDNA
library (Clontech) using TaqPlus (Stratagene) and cloned
into pPCRscript SK(+) (Stratagene). This partial cDNA
clone was sequenced and found to encode a novel CycT1
homolog. A radioactive probe was prepared from the clone
and used to screen a size-selected bovine cDNA phage
library (Clontech). Positive plaques were isolated and their
inserts amplified using PCR primers based on the vector
sequence and internal sequence of bCycT1. A clone con-
taining the largest N-terminal sequence (nts 1–1651) was
then used to generate another hybridization probe targeted to
the C terminus, the phage library was re-screened, and a
clone containing the remaining C-terminal sequence (nts
1051–2181) was isolated. The full-length bCycT1 gene
was constructed from these two cDNA clones (Genbank
Accession No. AY428555).
Transient transfection and CAT assays
NIH 3T3 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco-BRL) with 10% fetal
bovine serum, penicillin (100 units/ml), and streptomycin
(100 Ag/ml), and grown in 12-well plates to approximately
85% confluence for transfection experiments. Reporter and
expressor plasmids (typically 20 ng of the pHIV-LTR-CAT
reporter, 100 ng of the pSV2tat72 expressor, and varying
amounts of the pcDNA3 CycT1 vectors) were mixed with a
carrier Bluescript plasmid (adjusted to 1 Ag total DNA) in
250 Al Optimem low serum medium (BRL). A mixture of
Lipofectamine (Invitrogen) and Optimem [at a 1:62.5 (v/v)
ratio in 250 Al] was incubated at room temperature for 45
min, added to the DNA mixture, and incubated for an
additional 15 min. DNA was then added to cells that had
been grown in DMEM/10%FBS, washed with PBS, pre-
incubated in Optimem at 37 jC for 10 min, and washed
again with phosphate-buffered saline (PBS). After incubat-
ing at 37 jC for 4 h, the medium was removed and freshDMEM/10%FBS was added. Cells were grown for an
additional 48 h and harvested for CAT assays as described
previously (Chen and Frankel, 1994).
Sequence alignment and molecular graphics
The alignment of multiple cyclin sequences (obtained
from the Swiss Prot database; http://www.ebi.ac.uk/
swissprot/) was performed using ClustalW (1.8) with de-
fault parameters (European Bioinformatics Institute; http://
www.ebi.ac.uk/clustalw/). Atomic coordinates of cyclin A
(1FIN), cyclin H (1KXU), and cyclin M (1F5Q) were
obtained from the Protein Data Bank (http://www.rcsb.
org/pdb/), with cyclin A coordinates extracted from a cyclin
A-Cdk2 complex. Structures were visualized using the
program Molmol (Koradi et al., 1996) and aligned using
the ‘‘Fit’’ command with default parameters.Acknowledgments
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